<DOC>
	<DOCNO>NCT01134393</DOCNO>
	<brief_summary>The general aim trial determine efficacy measure percentage patient reach blood pressure goal end treatment period 12 week . In-clinic blood pressure , home blood pressure safety carefully monitor .</brief_summary>
	<brief_title>TElmisartan AMlodipine Single Pill sTudy With Patients Not Goal With Mono rAas Therapy-switch</brief_title>
	<detailed_description>Study Design :</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Telmisartan</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Inclusion criterion : 1 . Ability provide write informed consent accordance Good Clinical Practice local legislation 2 . Age 18 year old 3 . Patients uncontrolled hypertension define SBP &gt; 140 mmHg SBP &gt; 130 mmHg patient diabetes renal impairment DBP &gt; 90 mmHg DBP &gt; 80 mmHg patient diabetes renal impairment least 6 week stable treatment antihypertensive medication define treatment clinically recommend dose single RAAS blocking agent ( Angiotensin Converting Enzym inhibition , AII Receptor Blocker Direct Renin Inhibitor ) enter trial . Renal impairment define creatinine &gt; 133µmol/l ( 1.5mg/dl ) male patient creatinine &gt; 124µmol/l ( 1.3mg/dl ) female patient creatinine clearance 3060 ml/min Exclusion criterion : 1 . Premenopausal woman surgically sterile ; nursing pregnant ; practise acceptable mean birth control plan continue use acceptable mean birth control throughout study agree submit pregnancy test participation trial . Acceptable method birth control include transdermal patch , oral , implantable injectable contraceptive , sexual abstinence vasectomise partner . 2 . Known suspected secondary hypertension ( e.g. , renal artery stenosis phaeochromocytoma ) . 3 . Mean inclinic seat cuff Systolic BP &gt; 180 mmHg SBP &gt; 160 mmHg patient diabetes renal impairment Diastolic BP &gt; 110 mmHg DBP &gt; 100 mmHg patient diabetes renal impairment . Renal impairment define creatinine &gt; 133µmol/l ( 1.5mg/dl ) male patient creatinine &gt; 124µmol/l ( 1.3mg/dl ) female patient creatinine clearance 3060 ml/min . 4 . Renal dysfunction define follow laboratory parameter : Serum creatinine &gt; 3.0 mg/dl ( &gt; 265 ¿mol/L ) and/or know creatinine clearance &lt; 30 ml/min and/or clinical marker severe renal impairment . 5 . Bilateral renal artery stenosis , renal artery stenosis solitary kidney , postrenal transplant patient patient one kidney . 6 . Clinically relevant hypokalaemia hyperkalaemia ( i.e. , &lt; 3.5 &gt; 5.5 mEq/L ) . 7 . Uncorrected sodium volume depletion . 8 . Primary aldosteronism . 9 . Hereditary fructose intolerance . 10 . Congestive heart failure New York Heart Association functional class Congestive Heart Failure IIIIV ( Refer Appendix 10.1 ) . 11 . Clinically significant ventricular tachycardia , atrial fibrillation , atrial flutter clinically relevant cardiac arrhythmia determine Investigator . 12 . Biliary obstructive disorder ( e.g. , cholestasis ) hepatic insufficiency ( define elevate level &gt; 2x bilirubin &gt; 2x transaminase value ) . ( Refer Appendix 10.3 ) 13 . Patients previously experience symptom characteristic angioedema treatment ACE inhibitor angiotensinII receptor antagonist . 14 . History drug alcohol dependency within six month prior sign inform consent form . 15 . Any investigational drug therapy within one month signing informed consent . 16 . Known hypersensitivity component trial drug ( telmisartan amlodipine ) . 17 . History noncompliance inability comply prescribed medication protocol procedure . 18 . Any clinical condition , opinion investigator , would allow safe completion protocol safe administration trial medication .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>